Anemia, Autoimmune Hemolytic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AHA MCID: ANM038 MIFTS: 64	Anemia, Autoimmune Hemolytic (AHA) Categories: Blood diseases, Fetal diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Anemia, Autoimmune Hemolytic

MalaCards integrated aliases for Anemia, Autoimmune Hemolytic:

Name: Anemia, Autoimmune Hemolytic ⁵⁷

Autoimmune Hemolytic Anemia ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ¹⁴ ⁷¹

Idiopathic Autoimmune Hemolytic Anemia ¹⁹ ⁷¹

Anemia, Hemolytic, Autoimmune ⁴³ ¹⁶

Immuno-Hemolytic Anemia ¹⁹ ⁷¹

Familial Auto-Immune Hemolytic Anemia ¹⁹

Acquired Autoimmune Hemolytic Anemia ¹⁹

Autoimmune Haemolytic Anaemia ¹¹

Autoimmune Hemolytic Anaemia ¹¹

Anemia Hemolytic Autoimmune ¹⁹

Aiha ⁵⁸

Aha ⁵⁸

Characteristics:

Inheritance:

Anemia, Autoimmune Hemolytic: Autosomal recessive ⁵⁷

Autoimmune Hemolytic Anemia: Multigenic/multifactorial ⁵⁸

Prevelance:

Autoimmune Hemolytic Anemia: 1-9/100000 (Europe, United States) 1-5/10000 (Denmark) ⁵⁸

Age Of Onset:

Autoimmune Hemolytic Anemia: All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Fetal diseases Metabolic diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Haemolytic anaemias

Acquired haemolytic anaemia

Drug-induced autoimmune haemolytic anaemia

Other autoimmune haemolytic anaemias

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:718

OMIM® ⁵⁷ 205700

ICD9CM ³⁴ 283.0

MeSH ⁴³ D000744

NCIt ⁴⁹ C34378

SNOMED-CT ⁶⁸ 25121006

MESH via Orphanet ⁴⁴ D000744

ICD10 via Orphanet ³² D59.0 D59.1

UMLS via Orphanet ⁷² C0002880

Orphanet ⁵⁸ ORPHA98375

MedGen ⁴⁰ C0002880

EFO ¹⁶ EFO_1001264

UMLS ⁷¹ C0002880 C0543663 C2931849

Sources

Summaries for Anemia, Autoimmune Hemolytic

GARD: ¹⁹ Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells. This causes a drop in the number of red blood cells, leading to hemolytic anemia. Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties, jaundice, dark urine and/or splenomegaly. AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly.

MalaCards based summary: Anemia, Autoimmune Hemolytic, also known as autoimmune hemolytic anemia, is related to evans' syndrome and splenic marginal zone lymphoma. An important gene associated with Anemia, Autoimmune Hemolytic is TLR8 (Toll Like Receptor 8), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Innate Immune System. The drugs Tacrolimus and Calcineurin Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and heart, and related phenotypes are muscle weakness and fatigue

Orphanet: ⁵⁸ A rare, autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.

Disease Ontology: ¹¹ An autoimmune disease of blood that is characterized by deficient red blood cells caused by auto-antibodies.

Wikipedia: ⁷⁵ Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood... more...

More information from OMIM: 205700

Sources

Related Diseases for Anemia, Autoimmune Hemolytic

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic	Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia	Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder	Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies	Rare Hemolytic Anemia

Diseases related to Anemia, Autoimmune Hemolytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1141)

#	Related Disease	Score	Top Affiliating Genes
1	evans' syndrome	32.7	LRBA HP CTLA4 CD8A CD4 CD19
2	splenic marginal zone lymphoma	32.4	CD5 CD19 CCR6
3	autoimmune lymphoproliferative syndrome, type iia	32.4	CD8A CD4
4	common variable immunodeficiency	32.2	LRBA ICOSLG CTLA4 CD40LG CD19
5	autoimmune lymphoproliferative syndrome	32.2	LRBA ICOSLG CTLA4 CD8A CD40LG CD4
6	immunodysregulation, polyendocrinopathy, and enteropathy, x-linked	32.0	LRBA ICOSLG CTLA4 CD8A CD4 CCR6
7	leukemia, chronic lymphocytic	32.0	ICOSLG CTLA4 CD8A CD59 CD55 CD5
8	common cold	31.7	ICOSLG CD8A CD40LG CD4 CCR6
9	pure red-cell aplasia	31.7	HP CD8A CD4
10	thrombocytopenia due to platelet alloimmunization	31.7	SOCS1 ICOSLG CD8A CD4 CD19 CCR6
11	lymphoproliferative syndrome	31.6	LRBA CTLA4 CD5 CD40LG CCR6
12	thrombocytopenia	31.6	SOCS1 HP CTLA4 CD40LG CD4 C3
13	hemoglobinuria	31.6	HP G6PD CD59 CD55 C3
14	autoimmune disease	31.6	ICOSLG CTLA4 CD55 CD5 CD40LG CCR6
15	thrombocytopenic purpura, autoimmune	31.5	SOCS1 LRBA ICOSLG CD8A CD4 CCR6
16	agammaglobulinemia	31.4	TLR8 ICOSLG CD40LG CD19
17	aplastic anemia	31.4	CD8A CD59 CD55 CD4 CCR6
18	viral infectious disease	31.3	TLR8 ICOSLG CTLA4 CD40LG CD4 CCR6
19	colitis	31.3	SOCS1 ICOSLG CTLA4 CD4 CCR6
20	lupus erythematosus	31.3	SOCS1 CTLA4 CD40LG CCR6 C3 C1S
21	pernicious anemia	31.3	ICOSLG CD4 CCR6
22	erythema infectiosum	31.3	CD40LG CD4
23	agammaglobulinemia, x-linked	31.2	LRBA ICOSLG CD40LG CD19 CCR6
24	marginal zone b-cell lymphoma	31.2	ICOSLG CD5 CD19 CCR6
25	human cytomegalovirus infection	31.2	CD8A CD4 CCR6
26	hereditary spherocytosis	31.2	HP GYPA G6PD
27	primary biliary cholangitis	31.2	ICOSLG CTLA4 CD8A CD40LG CD4 CCR6
28	glomerulonephritis	31.2	CD59 CD55 CD40LG C3 C1S
29	pancytopenia	31.2	HP CD8A CD55 CD5 CD4 CD19
30	lymphopenia	31.2	CTLA4 CD59 CD55 CCR6
31	hepatitis a	31.1	GYPA G6PD CTLA4 CD4
32	paroxysmal nocturnal hemoglobinuria	31.1	HP G6PD CD59 CD55
33	sjogren syndrome	31.1	ICOSLG CD40LG CCR6
34	hashimoto thyroiditis	31.1	ICOSLG CTLA4 CD8A CD4 CCR6
35	sclerosing cholangitis	31.1	ICOSLG HP CD8A CD4 CCR6
36	pfeiffer syndrome	31.1	CD8A CD40LG CD4 CD19 CCR6
37	diffuse large b-cell lymphoma	31.1	ICOSLG CD5 CD19 CCR6
38	glucosephosphate dehydrogenase deficiency	31.1	RHCE HP GYPA G6PD
39	crohn's disease	31.1	ICOSLG HP CD8A CD4 CCR6
40	cryptococcal meningitis	31.1	CD8A CD4 CCR6
41	immune deficiency disease	31.0	ICOSLG CTLA4 CD8A CD5 CD40LG CD4
42	cholangitis, primary sclerosing	31.0	ICOSLG CTLA4 CD8A CD4 CCR6
43	bilirubin metabolic disorder	31.0	RHCE HP G6PD CD8A CD4
44	hemophagocytic lymphohistiocytosis	31.0	CTLA4 CD8A CD4 CD19 CCR6
45	cryoglobulinemia, familial mixed	31.0	CD5 CD40LG
46	exanthem	31.0	ICOSLG CTLA4 CD8A CD4 CD19 CCR6
47	myelodysplastic syndrome	31.0	SOCS1 ICOSLG GYPA CD8A CD59 CD55
48	waldenstroem's macroglobulinemia	31.0	CD59 CD5 CD40LG CD19
49	sarcoidosis 1	31.0	ICOSLG CD8A CD4 CCR6
50	autoimmune pancreatitis	31.0	ICOSLG CD4 CCR6

Comorbidity relations with Anemia, Autoimmune Hemolytic via Phenotypic Disease Network (PDN):

Acquired Thrombocytopenia	Acute Cystitis
Deficiency Anemia	Familial Atrial Fibrillation
Heart Disease	Leukemia, Chronic Lymphocytic
Neutropenia

Graphical network of the top 20 diseases related to Anemia, Autoimmune Hemolytic:

Sources

Symptoms & Phenotypes for Anemia, Autoimmune Hemolytic

Human phenotypes related to Anemia, Autoimmune Hemolytic:

⁵⁸ ³⁰ (show all 18)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	muscle weakness ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001324
2	fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012378
3	autoimmunity ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002960
4	hemolytic anemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001878
5	dyspnea ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002094
6	headache ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002315
7	abnormal leukocyte morphology ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001881
8	immunodeficiency ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002721
9	pallor ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000980
10	lymphoma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002665
11	splenomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001744
12	fever ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001945
13	congestive heart failure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001635
14	abdominal pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002027
15	arrhythmia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011675
16	abnormal urinary color ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012086
17	abnormality of metabolism/homeostasis ³⁰			HP:0001939
18	autoimmune hemolytic anemia ³⁰			HP:0001890

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Heme:
autoimmune hemolytic anemia

Lab:
coombs positive
abnormal immunoglobulin in heterozygotes

Clinical features from OMIM®:

205700 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Anemia, Autoimmune Hemolytic:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.03	C3 CCR6 CD19 CD4 CD40LG CD55
2	renal/urinary system	MP:0005367	9.91	C3 CD19 CD40LG CD55 CD59 CD8A
3	immune system	MP:0005387	9.86	C3 CCR6 CD19 CD4 CD40LG CD5
4	hematopoietic system	MP:0005397	9.58	C3 CCR6 CD19 CD4 CD40LG CD5

Sources

Drugs & Therapeutics for Anemia, Autoimmune Hemolytic

Drugs for Anemia, Autoimmune Hemolytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Calcineurin Inhibitors

Phase 4

Rituximab

Approved

Phase 3

174722-31-7

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Alemtuzumab

Approved, Investigational

Phase 2, Phase 3

216503-57-0

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Mycophenolic acid

Approved, Investigational

Phase 3

24280-93-1

446541

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Immunologic Factors

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Neuroprotective Agents

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Antiemetics

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

Methylprednisolone Acetate

Phase 3

584547

Gastrointestinal Agents

Phase 3

Protective Agents

Phase 3

Cyclosporins

Phase 3

Antifungal Agents

Phase 3

Dermatologic Agents

Phase 3

Pharmaceutical Solutions

Phase 3

Antirheumatic Agents

Phase 3

Anti-Infective Agents

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Anti-Bacterial Agents

Phase 3

Antitubercular Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Agglutinins

Phase 3

Chrysarobin

Phase 3

Autoantibodies

Phase 2, Phase 3

Levamisole

Approved, Investigational, Vet_approved, Withdrawn

Phase 2

14769-73-4

26879

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

Lactitol

Approved, Investigational

Phase 1, Phase 2

585-86-4

157355

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Acyclovir

Approved

Phase 2

59277-89-3

2022

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Eculizumab

Approved, Investigational

Phase 2

219685-50-4

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Interventional clinical trials:

(show top 50) (show all 62)

#	Name	Status	NCT ID	Phase	Drugs
1	Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Unknown status	NCT03918265	Phase 4	Tacrolimus
2	Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.	Completed	NCT01134432	Phase 3	prednisolone + mabthera;Prednisolone
3	Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial	Completed	NCT01181154	Phase 3	rituximab (Mabthera®);Placebo
4	Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias	Completed	NCT00749112	Phase 2, Phase 3	Alemtuzumab, Rituximab
5	A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion	Completed	NCT03347396	Phase 3	BIVV009
6	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion	Completed	NCT03347422	Phase 3	sutimlimab (BIVV009);placebo
7	Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia	Recruiting	NCT05057468	Phase 3	Cyclosporine;Rituximab
8	Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension	Recruiting	NCT04119050	Phase 2, Phase 3	M281;Placebo
9	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia	Recruiting	NCT05073458	Phase 3	parsaclisinib;placebo
10	A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)	Recruiting	NCT05096403	Phase 3	Pegcetacoplan
11	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Active, not recruiting	NCT03764618	Phase 3	Fostamatinib disodium;Placebo
12	Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Active, not recruiting	NCT05057481	Phase 3	Mycophenolate Mofetil 500mg;Rituximab
13	An Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in Japan	Active, not recruiting	NCT05132127	Phase 3	sutimlimab
14	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Enrolling by invitation	NCT04138927	Phase 3	Fostamatinib disodium
15	A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Not yet recruiting	NCT05535933	Phase 2, Phase 3	HMPL-523(300mg PO QD);Placebo
16	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach	Unknown status	NCT03827603	Phase 2	Ibrutinib
17	An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)	Unknown status	NCT03226678	Phase 2	APL-2
18	Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.	Unknown status	NCT01579110	Phase 2	levamisole;Prednisone
19	A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Completed	NCT02612558	Phase 2	Fostamatinib 150 mg bid
20	A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia	Completed	NCT01345708	Phase 2	prednisone, low dose rituximab
21	The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy	Completed	NCT02689986	Phase 2	Bendamustine, Rituximab
22	" Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment	Completed	NCT02389231	Phase 1, Phase 2	Interleukine-2
23	Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series	Completed	NCT00392951	Phase 1, Phase 2	sirolimus
24	Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease	Completed	NCT00010387	Phase 2	cyclophosphamide;filgrastim
25	Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease	Completed	NCT01696474	Phase 2	Bortezomib
26	Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.	Completed	NCT00373594	Phase 2	Rituximab;Fludarabine
27	CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)	Completed	NCT00309881	Phase 2	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28	Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab	Completed	NCT01303952	Phase 2	Eculizumab
29	An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia	Recruiting	NCT04083014	Phase 2	combination of a single dose anti-CD20 antibody and bortezomib
30	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)	Recruiting	NCT04691570	Phase 2	ANX005
31	A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia	Recruiting	NCT04661033	Phase 1, Phase 2	Isatuximab SAR650984
32	Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study	Recruiting	NCT05089227	Phase 2	treatment "intervention";treatment "standard"
33	A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia	Recruiting	NCT05002777	Phase 2	rilzabrutinib
34	A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic	Recruiting	NCT04398459	Phase 2	Ibrutinib
35	An Open-label, Multi-center, Phase 2 Basket Study to Assess Efficacy, Safety and Pharmacokinetics of Iptacopan (LNP023) in Participants With Autoimmune Benign Hematological Disorders	Recruiting	NCT05086744	Phase 2	Iptacopan
36	A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia	Active, not recruiting	NCT04657094	Phase 2	Acalabrutinib
37	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Active, not recruiting	NCT03538041	Phase 2	Parsaclisib
38	A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)	Terminated	NCT03075878	Phase 1, Phase 2	ALXN1830
39	A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia	Terminated	NCT04253236	Phase 2	RVT-1401 680 mg/weekly;RVT-1401 340 mg/weekly
40	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia	Withdrawn	NCT04256148	Phase 2
41	A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP)	Withdrawn	NCT04039477	Phase 2	KZR-616
42	A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)	Withdrawn	NCT04956276	Phase 2	ALXN1830;Placebo
43	A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia	Withdrawn	NCT03965624	Phase 2	Ninlaro
44	Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.	Completed	NCT02502903	Phase 1	BIV009
45	High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia	Completed	NCT00001630	Phase 1
46	A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease	Completed	NCT04269551	Phase 1	BIVV020
47	An Open Label, Long Term, Safety and Tolerability Study of Patients With Cold Agglutinin Disease Previously Treated With BIVV020	Active, not recruiting	NCT04802057	Phase 1	BIVV020
48	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases	Unknown status	NCT00006055		anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
49	Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome	Unknown status	NCT03912129
50	Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia in Assiut University Hospital	Completed	NCT03269292

Search NIH Clinical Center for Anemia, Autoimmune Hemolytic

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cyclophosphamide

Immunoglobulins, Intravenous

Cochrane evidence based reviews: anemia, hemolytic, autoimmune

Sources

Genetic Tests for Anemia, Autoimmune Hemolytic

Genetic tests related to Anemia, Autoimmune Hemolytic:

#	Genetic test	Affiliating Genes
1	Autoimmune Hemolytic Anemia ²⁸

Sources

Anatomical Context for Anemia, Autoimmune Hemolytic

Organs/tissues related to Anemia, Autoimmune Hemolytic:

MalaCards : T Cells, Bone Marrow, Heart, B Cells, Liver, Spleen, Bone

Sources

Publications for Anemia, Autoimmune Hemolytic

Articles related to Anemia, Autoimmune Hemolytic:

(show top 50) (show all 4523)

#	Title	Authors	PMID	Year
1	TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins. ⁶² ⁵	Fejtkova M...Kanderova V	34981838	2022
2	Familial autoimmune haemolytic anaemia. ⁶² ⁵⁷	Toolis F...Urbaniak S	861649	1977
3	[Familial autoimmune hemolytic animia (AIHA) with negative Coombs test, lymphocytopenia and hypogammaglobulinemia]. ⁶² ⁵⁷	Roth P...Bucher U	1209224	1975
4	Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis. ⁶² ⁵⁷	Pirofsky B	5660845	1968
5	FAMILIAL AUTO-IMMUNE HEMOLYTIC ANEMIA. ⁶² ⁵⁷	DOBBS CE	14315660	1965
6	Immuno-hemolytic anemia with familial occurence. ⁶² ⁵⁷	KISSMEYER-NIELSEN F...KIELER J	13007407	1952
7	Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. ⁵	Aluri J...Cooper MA	33512449	2021
8	"ACQUIRED" ANTIBODY HEMOLYTIC ANEMIA AND FAMILIAL ABERRATIONS IN GAMMA GLOBULINS. ⁵⁷	FIALKOW PJ...EPSTEIN WV	14124686	1964
9	Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. ⁵³ ⁶²	Shichishima T...Sawada K	20376581	2010
10	Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. ⁵³ ⁶²	Shinoda K...Tobe K	20374393	2010
11	Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. ⁵³ ⁶²	Arndt PA...Garratty G	18980619	2009
12	Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. ⁵³ ⁶²	Barros MM...Bordin JO	18954403	2009
13	[Density-specific distribution of erythrocytes in different types of anemia]. ⁵³ ⁶²	Shurkhina ES...Ataullakhanov FI	19253711	2009
14	Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia. ⁵³ ⁶²	Ozbay Hosnut F...Ozbek N	18320220	2008
15	The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. ⁵³ ⁶²	Ruiz-Arguelles A...Llorente L	17289551	2007
16	Aortic valve replacement for a patient with glucose-6-phosphate dehydrogenase deficiency and autoimmune hemolytic anemia. ⁵³ ⁶²	Tas S...Yakut C	15985145	2005
17	Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. ⁵³ ⁶²	Kedar PS...Mohanty D	14641141	2003
18	Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. ⁵³ ⁶²	Dupuis-Girod S...Fischer A	12728121	2003
19	Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. ⁵³ ⁶²	Bencomo AA...Alfonso ME	15373694	2003
20	Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. ⁵³ ⁶²	Stahl D...Sibrowski W	12871191	2003
21	[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]. ⁵³ ⁶²	Gao W...Zhou Y	11930678	2001
22	[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test]. ⁵³ ⁶²	Meyer F...Rigal D	10472686	1999
23	Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. ⁵³ ⁶²	Friedmann AM...Casella JF	9787330	1998
24	Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti-red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A. ⁵³ ⁶²	Leddy JP...Rosenfeld SI	7517724	1994
25	Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. ⁶²	Cooper N...Kessler C	36331249	2023
26	Hematologic and Oncologic Emergencies. ⁶²	Holden K...Balaan M	36415070	2023
27	Splenectomy as an effective treatment for macrothrombocytopenia in Takenouchi-Kosaki syndrome. ⁶²	Yamano S...Ishiguro A	36459360	2022
28	An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database. ⁶²	Pham HP...Joly F	36427340	2022
29	Splenectomy outcomes in patients with autoimmune cytopenias and persistent antiphospholipid antibodies. ⁶²	Rangel-Patino J...Demichelis-Gomez R	36208143	2022
30	Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). ⁶²	Erton ZB...Erkan D	36206383	2022
31	Activating de novo monoallelic variants causing inborn errors of immunity in two unrelated children born of HIV-seroconcordant couples. ⁶²	Lugo Reyes SO...Murata C	36382434	2022
32	Blinding Anemia: A Case of Bilateral Sequential Nonarteritic Ischemic Optic Neuropathy Secondary to Warm Autoimmune Hemolytic Anemia. ⁶²	O'Keeffe B...Aburn N	34803137	2022
33	Systemic loxoscelism induced warm autoimmune hemolytic anemia: clinical series and review. ⁶²	Calhoun B...Shoemaker DM	35544675	2022
34	Cold-type autoimmune hemolytic anaemia in a patient with primary bone marrow diffuse large B-cell lymphoma. ⁶²	Sundaresan DD...Malhotra P	35975908	2022
35	Influence of immunohematological markers on severity of in vivo hemolysis in human warm autoimmune haemolytic anemia. ⁶²	Das SS...Mukherjee S	35773127	2022
36	Targeted next-generation sequencing revealed a novel homozygous mutation in the LRBA gene causes severe haemolysis associated with Inborn Errors of Immunity in an Indian family. ⁶²	Kedar P...Madkaikar M	35413226	2022
37	Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. ⁶²	Roth A...Weitz IC	36403132	2022
38	Autoimmune haemolytic anaemia. ⁶²	Arguello Marina M...Castilla Garcia L	36334945	2022
39	Autoimmune haemolytic anaemia due to immunodeficiency. ⁶²	Samitinjay A...Biswas R	36414334	2022
40	Thalidomide-associated autoimmune hemolytic anemia. ⁶²	Wu Y...Liu X	36349983	2022
41	Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review. ⁶²	Huang HE...Cheng TT	36355549	2022
42	Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia. ⁶²	Zhang R...Han B	36066607	2022
43	Autoimmune Hemolytic Anemia in Inflammatory Bowel Disease-Report of a Case and Review of the Literature. ⁶²	Toplicanin A...Sokic Milutinovic A	36362944	2022
44	Novel loss-of-function mutations in TNFAIP3 gene in patients with lupus nephritis. ⁶²	Zhang C...Zhou Q	36325013	2022
45	Post-traumatic growth in adult patients with systemic lupus erythematosus: a cross-sectional study in China. ⁶²	Xu R...Yin R	36255484	2022
46	Systemic lupus erythematosus with disseminated aspergillosis misdiagnosed as lupus encephalopathy: a case report and literature review. ⁶²	Yan X...Wang B	36388809	2022
47	Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. ⁶²	Martin M...French Network of Regional Pharmacovigilance Centers	36291814	2022
48	Ruptured dermoid cyst of ovary developing into chronic peritonitis; a rare complication diagnosed by contrast CT: A case study. ⁶²	Rai K...Timilsina B	36268424	2022
49	Diagnosis and Management of Autoimmune Hemolytic Anemias. ⁶²	Barcellini W...Fattizzo B	36294350	2022
50	Red blood cell alloimmunization and other transfusion-related complications in patients with transfusion-dependent thalassemia: A multi-center study in Thailand. ⁶²	Teawtrakul N...Red Blood Cell Disorders Study Group	35986658	2022

Sources

Genes for Anemia, Autoimmune Hemolytic

Genes related to Anemia, Autoimmune Hemolytic (2 elite genes):

(show all 40)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TLR8	Toll Like Receptor 8	Protein Coding	403.65	Pathogenic ⁵ DISEASES inferred ¹⁴	34981838 33512449
2	TLR8-AS1	TLR8 Antisense RNA 1	RNA Gene	400	Pathogenic ⁵	34981838 33512449
3	SOCS1	Suppressor Of Cytokine Signaling 1	Protein Coding	28.84	Likely pathogenic ⁵ DISEASES inferred ¹⁴
4	HP	Haptoglobin	Protein Coding	15.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20376581
5	CD59	CD59 Molecule (CD59 Blood Group)	Protein Coding	12.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11930678 18954403 17289551
6	CD55	CD55 Molecule (Cromer Blood Group)	Protein Coding	11.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11930678 18954403 17289551
7	CD40LG	CD40 Ligand	Protein Coding	11.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20374393 12728121 12871191 (more) 10472686 9787330 15373694 18980619
8	GYPA	Glycophorin A (MNS Blood Group)	Protein Coding	10.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7517724
9	G6PD	Glucose-6-Phosphate Dehydrogenase	Protein Coding	10.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15985145 18320220 19253711 (more) 14641141
10	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.8	DISEASES inferred ¹⁴ ¹⁴
11	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	7.23	DISEASES inferred ¹⁴ ¹⁴
12	LRBA	LPS Responsive Beige-Like Anchor Protein	Protein Coding	7.13	DISEASES inferred ¹⁴
13	CD4	CD4 Molecule	Protein Coding	7	DISEASES inferred ¹⁴
14	CD8A	CD8a Molecule	Protein Coding	6.73	DISEASES inferred ¹⁴
15	RHCE	Rh Blood Group CcEe Antigens	Protein Coding	6.68	DISEASES inferred ¹⁴
16	CD19	CD19 Molecule	Protein Coding	6.64	DISEASES inferred ¹⁴
17	CD5	CD5 Molecule	Protein Coding	6.58	DISEASES inferred ¹⁴
18	C3	Complement C3	Protein Coding	6.52	DISEASES inferred ¹⁴
19	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	6.48	DISEASES inferred ¹⁴
20	C1S	Complement C1s	Protein Coding	6.3	DISEASES inferred ¹⁴
21	BTK	Bruton Tyrosine Kinase	Protein Coding	6.22	DISEASES inferred ¹⁴
22	CD52	CD52 Molecule	Protein Coding	6.16	DISEASES inferred ¹⁴
23	TNFRSF13B	TNF Receptor Superfamily Member 13B	Protein Coding	6.15	DISEASES inferred ¹⁴
24	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	6.11	DISEASES inferred ¹⁴
25	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	6.1	DISEASES inferred ¹⁴
26	IL2	Interleukin 2	Protein Coding	6.09	DISEASES inferred ¹⁴
27	ADAMTS13	ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13	Protein Coding	6.09	DISEASES inferred ¹⁴
28	FOXP3	Forkhead Box P3	Protein Coding	6.07	DISEASES inferred ¹⁴
29	CR2	Complement C3d Receptor 2	Protein Coding	6.05	DISEASES inferred ¹⁴
30	STIM1	Stromal Interaction Molecule 1	Protein Coding	6.04	DISEASES inferred ¹⁴
31	CD38	CD38 Molecule	Protein Coding	6.03	DISEASES inferred ¹⁴
32	CD27	CD27 Molecule	Protein Coding	6.03	DISEASES inferred ¹⁴
33	RHD	Rh Blood Group D Antigen	Protein Coding	6.02	DISEASES inferred ¹⁴
34	IL10	Interleukin 10	Protein Coding	6	DISEASES inferred ¹⁴
35	ZAP70	Zeta Chain Of T Cell Receptor Associated Protein Kinase 70	Protein Coding	5.99	DISEASES inferred ¹⁴
36	APOH	Apolipoprotein H	Protein Coding	5.93	DISEASES inferred ¹⁴
37	CRP	C-Reactive Protein	Protein Coding	5.9	DISEASES inferred ¹⁴
38	IL6	Interleukin 6	Protein Coding	5.86	DISEASES inferred ¹⁴
39	EPO	Erythropoietin	Protein Coding	5.85	DISEASES inferred ¹⁴
40	RAG1	Recombination Activating 1	Protein Coding	5.85	DISEASES inferred ¹⁴

Sources

Variations for Anemia, Autoimmune Hemolytic

ClinVar genetic disease variations for Anemia, Autoimmune Hemolytic:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TLR8-AS1, TLR8	NM_138636.5(TLR8):c.1715G>T (p.Gly572Val)	SNV	Pathogenic	1339649		GRCh37: X:12938874-12938874 GRCh38: X:12920755-12920755
2	SOCS1	NM_003745.2(SOCS1):c.476_480dup (p.Met161fs)	MICROSAT	Likely Pathogenic	977214	rs1470306246	GRCh37: 16:11348855-11348856 GRCh38: 16:11254998-11254999
3	SOCS1	NM_003745.2(SOCS1):c.24del (p.Ala9fs)	DEL	Likely Pathogenic	977213	rs2069587477	GRCh37: 16:11349312-11349312 GRCh38: 16:11255455-11255455
4	TLR8-AS1, TLR8	NM_138636.5(TLR8):c.2498T>C (p.Phe833Ser)	SNV	Uncertain Significance	1339650		GRCh37: X:12939657-12939657 GRCh38: X:12921538-12921538

Sources

Expression for Anemia, Autoimmune Hemolytic

Search GEO for disease gene expression data for Anemia, Autoimmune Hemolytic.

Sources

Pathways for Anemia, Autoimmune Hemolytic

Pathways related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

(show all 17)

#	Super pathways	Score	Top Affiliating Genes
1	Class I MHC mediated antigen processing and presentation ⁶⁶ Show member pathways Adaptive Immune System ⁶⁶ Antigen processing: Ubiquitination and Proteasome degradation ⁶⁶ Neddylation ⁶⁶	13.37	SOCS1 ICOSLG CTLA4 CD8A CD40LG CD4
2	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.35	TLR8 SOCS1 ICOSLG HP CTLA4 CD8A
3	Complement cascade ⁶⁶ Show member pathways Activation of C3 and C5 ⁶⁶ Classical Complement Pathway ⁶⁴ Complement Pathway ⁶⁴ Complement system ⁷⁴ Complement system in neuronal development and plasticity ⁷⁴ Lectin Induced Complement Pathway ⁶⁴ Regulation of Complement cascade ⁶⁶	12.45	CD59 CD55 CD19 C3 C1S
4	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.24	ICOSLG CTLA4 CD8A CD4
5	NF-kappaB Signaling ³	12.15	TLR8 SOCS1 CTLA4 CD8A CD40LG CD19
6	CD28 Signaling in T-Helper Cell ⁶⁴ Show member pathways ICos-ICosL Pathway in T-Helper Cell ⁶⁴	12.1	ICOSLG CTLA4 CD40LG CD4
7	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.96	CTLA4 CD8A CD40LG CD4
8	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell ⁶⁶	11.88	CD8A CD40LG CD19 C3
9	Initial triggering of complement ⁶⁶ Show member pathways Alternative complement activation ⁶⁶ Alternative Complement Pathway ⁶⁴ Classical antibody-mediated complement activation ⁶⁶ Complement activation ⁷⁴ Complement Activation Pathways ⁶⁷ Creation of C4 and C2 activators ⁶⁶ Ficolins bind to repetitive carbohydrate structures on the target cell surface ⁶⁶ Lectin pathway of complement activation ⁶⁶	11.79	CD59 CD55 C3 C1S
10	Immune response Lectin induced complement pathway ²² Show member pathways Immune response Alternative complement pathway ²² Immune response Classical complement pathway ²² Terminal pathway of complement ⁶⁶	11.74	C1S C3 CD55 CD59
11	Innate Lymphoid Cells Differentiation ⁶⁵	11.65	CD8A CD4 CCR6
12	Allograft rejection ⁷⁴	11.64	CTLA4 CD55 CD40LG C3
13	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.59	CD8A CD4 CD19
14	Acute viral myocarditis ⁷⁴	11.5	SOCS1 CD55 CD40LG CD4
15	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.41	ICOSLG CD40LG CD19 C3
16	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.37	CTLA4 SOCS1 TLR8
17	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.16	GYPA CD8A CD59 CD5 CD4 CD19

Sources

GO Terms for Anemia, Autoimmune Hemolytic

Cellular components related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005887	10.09	CCR6 CD19 CD4 CD40LG CD5 CD8A
2	plasma membrane	GO:0005886	10.09	CCR6 CD19 CD4 CD40LG CD5 CD8A
3	external side of plasma membrane	GO:0009897	9.6	TLR8 ICOSLG CTLA4 CD8A CD59 CD5

Biological processes related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	9.7	CTLA4 CD8A CD40LG CD4 CCR6 C3
2	regulation of cytokine production	GO:0001817	9.65	TLR8 SOCS1 ICOSLG
3	regulation of complement activation	GO:0030449	9.62	CD59 CD55
4	regulation of complement-dependent cytotoxicity	GO:1903659	9.46	CD59 CD55
5	immune system process	GO:0002376	9.36	TLR8 ICOSLG HP CTLA4 CD8A CD55